View Future GrowthFoosung 과거 순이익 실적과거 기준 점검 2/6Foosung의 수입은 연평균 -50.6%의 비율로 감소해 온 반면, Chemicals 산업은 수입이 연평균 1.2% 증가했습니다. 매출은 연평균 5.9%의 비율로 증가해 왔습니다. Foosung의 자기자본이익률은 1.8%이고 순이익률은 1.1%입니다.핵심 정보-50.64%순이익 성장률-49.51%주당순이익(EPS) 성장률Chemicals 산업 성장률13.95%매출 성장률5.94%자기자본이익률1.81%순이익률1.13%최근 순이익 업데이트31 Dec 2025최근 과거 실적 업데이트Reported Earnings • Mar 21Full year 2024 earnings: EPS and revenues miss analyst expectationsFull year 2024 results: ₩668 loss per share (further deteriorated from ₩556 loss in FY 2023). Revenue: ₩437.8b (down 16% from FY 2023). Net loss: ₩69.4b (loss widened 29% from FY 2023). Revenue missed analyst estimates by 6.6%. Earnings per share (EPS) were also behind analyst expectations. Revenue is forecast to grow 21% p.a. on average during the next 2 years, compared to a 11% growth forecast for the Chemicals industry in South Korea. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 57 percentage points per year, which is a significant difference in performance.Reported Earnings • Mar 24Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behindFull year 2022 results: EPS: ₩1,047 (up from ₩244 in FY 2021). Revenue: ₩610.6b (up 60% from FY 2021). Net income: ₩97.0b (up 330% from FY 2021). Profit margin: 16% (up from 5.9% in FY 2021). The increase in margin was driven by higher revenue. Revenue exceeded analyst estimates by 2.0%. Earnings per share (EPS) missed analyst estimates by 20%. Revenue is forecast to grow 17% p.a. on average during the next 3 years, compared to a 16% growth forecast for the Chemicals industry in South Korea. Over the last 3 years on average, earnings per share has increased by 101% per year but the company’s share price has only increased by 32% per year, which means it is significantly lagging earnings growth.Reported Earnings • Mar 25Full year 2020 earnings released: EPS ₩65.00 (vs ₩87.00 in FY 2019)The company reported a soft full year result with weaker earnings and profit margins, although revenues improved. Full year 2020 results: Revenue: ₩261.6b (up 5.1% from FY 2019). Net income: ₩5.99b (down 26% from FY 2019). Profit margin: 2.3% (down from 3.3% in FY 2019). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 70 percentage points per year, which is a significant difference in performance.모든 업데이트 보기Recent updatesMajor Estimate Revision • May 19Consensus EPS estimates fall by 28%, revenue upgradedThe consensus outlook for fiscal year 2026 has been updated. 2026 revenue forecast increased from ₩564.8m to ₩592.8m. EPS estimate fell from ₩288 to ₩206 per share. Net income forecast to grow 316% next year vs 62% growth forecast for Chemicals industry in South Korea. Consensus price target of ₩20,000 unchanged from last update. Share price fell 4.6% to ₩11,830 over the past week.New Risk • May 15New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of South Korean stocks, typically moving 17% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Interest payments are not well covered by earnings (2.0x net interest cover). Share price has been highly volatile over the past 3 months (17% average weekly change).Buy Or Sell Opportunity • May 04Now 28% overvalued after recent price riseOver the last 90 days, the stock has risen 69% to ₩14,130. The fair value is estimated to be ₩11,060, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has declined by 12% over the last 3 years. Meanwhile, the company has become profitable. For the next 3 years, revenue is forecast to grow by 16% per annum. Earnings are also forecast to grow by 52% per annum over the same time period.Major Estimate Revision • Apr 24Consensus EPS estimates increase by 57%, revenue downgradedThe consensus outlook for fiscal year 2026 has been updated. 2026 revenue forecast fell from ₩579.5m to ₩564.8m. EPS estimate rose from ₩183 to ₩288. Net income forecast to grow 482% next year vs 62% growth forecast for Chemicals industry in South Korea. Consensus price target up from ₩12,000 to ₩20,000. Share price fell 5.4% to ₩13,070 over the past week.New Risk • Apr 04New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 13% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Interest payments are not well covered by earnings (2.0x net interest cover). Minor Risk Share price has been volatile over the past 3 months (13% average weekly change).New Risk • Apr 02New major risk - Revenue and earnings growthEarnings have declined by 57% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Interest payments are not well covered by earnings (1.5x net interest cover). Earnings have declined by 57% per year over the past 5 years.분석 기사 • Jan 28Foosung Co., Ltd. (KRX:093370) Not Lagging Industry On Growth Or PricingWhen you see that almost half of the companies in the Chemicals industry in Korea have price-to-sales ratios (or "P/S...분석 기사 • Oct 28Revenues Tell The Story For Foosung Co., Ltd. (KRX:093370) As Its Stock Soars 62%Despite an already strong run, Foosung Co., Ltd. ( KRX:093370 ) shares have been powering on, with a gain of 62% in the...New Risk • Oct 27New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of South Korean stocks, typically moving 11% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Interest payments are not well covered by earnings (0.7x net interest cover). Share price has been highly volatile over the past 3 months (11% average weekly change).공시 • Oct 24Foosung Co., Ltd. announced that it expects to receive KRW 27 billion in fundingFoosung Co., Ltd. announced private placement of Series 2 Zero Coupon Registered Unsecured Private Convertible Bonds due November 05, 2030 for gross proceeds of KRW 27,000,000,000 on October 23, 2025. The transaction includes participation from Heimdall No.2 PEF for KRW 20,000,000,000 and Fluoro Mateiral New Technology Fund for KRW 7,000,000,000. The bonds bear no interest rate and have a yield to maturity rate of 5.7%. The bonds will mature on November 05, 2030. The bonds are 100% convertible into 3,937,582 shares at a conversion price of KRW 6,857 from the conversion period of November 05, 2026 to October 05, 2030. The bonds have a restriction period of 1 year. The transaction is approved by board of directors of the company and is expected to close on November 05, 2025.분석 기사 • Oct 17There's Been No Shortage Of Growth Recently For Foosung's (KRX:093370) Returns On CapitalIf we want to find a stock that could multiply over the long term, what are the underlying trends we should look for...New Risk • Sep 15New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 7.7% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Interest payments are not well covered by earnings (0.7x net interest cover). Minor Risk Share price has been volatile over the past 3 months (7.7% average weekly change).분석 기사 • Aug 18Foosung Co., Ltd. (KRX:093370) Stocks Shoot Up 30% But Its P/S Still Looks ReasonableKOSE:A093370 1 Year Share Price vs Fair Value Explore Foosung's Fair Values from the Community and select yours Despite...분석 기사 • Aug 14Is Foosung (KRX:093370) A Risky Investment?Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...분석 기사 • Jun 10Potential Upside For Foosung Co., Ltd. (KRX:093370) Not Without RiskThere wouldn't be many who think Foosung Co., Ltd.'s ( KRX:093370 ) price-to-sales (or "P/S") ratio of 1.2x is worth a...Major Estimate Revision • May 02Consensus EPS estimates have been downgraded.The consensus outlook for earnings per share (EPS) in fiscal year 2025 has deteriorated. 2025 revenue forecast decreased from ₩567.0m to ₩550.9m. Now expected to report a loss of ₩49.00 per share instead of ₩69.00 per share profit previously forecast. Chemicals industry in South Korea expected to see average net income growth of 35% next year. Consensus price target down from ₩14,000 to ₩10,000. Share price was steady at ₩4,400 over the past week.Reported Earnings • Mar 21Full year 2024 earnings: EPS and revenues miss analyst expectationsFull year 2024 results: ₩668 loss per share (further deteriorated from ₩556 loss in FY 2023). Revenue: ₩437.8b (down 16% from FY 2023). Net loss: ₩69.4b (loss widened 29% from FY 2023). Revenue missed analyst estimates by 6.6%. Earnings per share (EPS) were also behind analyst expectations. Revenue is forecast to grow 21% p.a. on average during the next 2 years, compared to a 11% growth forecast for the Chemicals industry in South Korea. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 57 percentage points per year, which is a significant difference in performance.분석 기사 • Mar 18Would Foosung (KRX:093370) Be Better Off With Less Debt?Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...공시 • Feb 19Foosung Co., Ltd., Annual General Meeting, Mar 25, 2025Foosung Co., Ltd., Annual General Meeting, Mar 25, 2025, at 10:00 Tokyo Standard Time. Location: auditorium, 72-37, hyundaikia-ro, paltan-myeon, gyeonggi-do, hwaseong South KoreaNew Risk • Jan 24New major risk - Revenue and earnings growthEarnings have declined by 15% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 15% per year over the past 5 years. Minor Risk High level of debt (67% net debt to equity).분석 기사 • Nov 23The Price Is Right For Foosung Co., Ltd. (KRX:093370)When you see that almost half of the companies in the Chemicals industry in Korea have price-to-sales ratios (or "P/S...분석 기사 • Aug 05Foosung Co., Ltd.'s (KRX:093370) Share Price Is Still Matching Investor Opinion Despite 29% SlumpThe Foosung Co., Ltd. ( KRX:093370 ) share price has fared very poorly over the last month, falling by a substantial...Major Estimate Revision • May 24Consensus revenue estimates fall by 16%The consensus outlook for revenues in fiscal year 2024 has deteriorated. 2024 revenue forecast decreased from ₩612.4m to ₩516.6m. Forecast loss of -₩107, down from profit of ₩91.00 per share profit previously. Chemicals industry in South Korea expected to see average net income growth of 31% next year. Consensus price target down from ₩20,000 to ₩17,000. Share price fell 3.6% to ₩7,010 over the past week.New Risk • May 01New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 14% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risk Debt is not well covered by operating cash flow (currently running at an operating cash loss). Minor Risk Shareholders have been diluted in the past year (14% increase in shares outstanding).공시 • Jan 26Foosung Co., Ltd. has filed a Follow-on Equity Offering in the amount of KRW 101.290324 billion.Foosung Co., Ltd. has filed a Follow-on Equity Offering in the amount of KRW 101.290324 billion. Security Name: Common Stock Security Type: Common Stock Securities Offered: 12,903,226 Price\Range: KRW 7850 Discount Per Security: KRW 39.25 Transaction Features: ESOP Related Offering; Rights OfferingValuation Update With 7 Day Price Move • Jan 26Investor sentiment deteriorates as stock falls 16%After last week's 16% share price decline to ₩8,620, the stock trades at a forward P/E ratio of 52x. Average forward P/E is 11x in the Chemicals industry in South Korea. Total loss to shareholders of 28% over the past three years.Upcoming Dividend • Dec 20Upcoming dividend of ₩20.00 per share at 0.2% yieldEligible shareholders must have bought the stock before 27 December 2023. Payment date: 08 April 2024. Payout ratio is a comfortable 17% but the company is not cash flow positive. Trailing yield: 0.2%. Lower than top quartile of South Korean dividend payers (3.5%). Lower than average of industry peers (1.8%).New Risk • Aug 23New minor risk - Profit margin trendThe company's profit margins are lower than last year and have reduced by more than 30%. Net profit margin: 5.8% Last year net profit margin: 14% This is considered a minor risk. A large drop in profit margin could indicate the company does not have strong competitive advantages or it is yet to establish itself and its core business. Even if it is a well established business, this may make it a much riskier investment than one that has a combination of proven competitive advantages and a stable or growing profit margin. Currently, the following risks have been identified for the company: Major Risks Interest payments are not well covered by earnings (0.1x net interest cover). High level of non-cash earnings (26% accrual ratio). Minor Risk Profit margins are more than 30% lower than last year (5.8% net profit margin).New Risk • Aug 16New major risk - Revenue and earnings growthEarnings are forecast to decline by an average of 0.1% per year for the foreseeable future. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are expected to decline, then in most cases the share price will decline over time as well. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Interest payments are not well covered by earnings (2.6x net interest cover). Earnings are forecast to decline by an average of 0.1% per year for the foreseeable future. High level of non-cash earnings (22% accrual ratio).Valuation Update With 7 Day Price Move • Mar 29Investor sentiment improves as stock rises 30%After last week's 30% share price gain to ₩16,620, the stock trades at a trailing P/E ratio of 16.2x. Average forward P/E is 11x in the Chemicals industry in South Korea. Total returns to shareholders of 174% over the past three years.Reported Earnings • Mar 24Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behindFull year 2022 results: EPS: ₩1,047 (up from ₩244 in FY 2021). Revenue: ₩610.6b (up 60% from FY 2021). Net income: ₩97.0b (up 330% from FY 2021). Profit margin: 16% (up from 5.9% in FY 2021). The increase in margin was driven by higher revenue. Revenue exceeded analyst estimates by 2.0%. Earnings per share (EPS) missed analyst estimates by 20%. Revenue is forecast to grow 17% p.a. on average during the next 3 years, compared to a 16% growth forecast for the Chemicals industry in South Korea. Over the last 3 years on average, earnings per share has increased by 101% per year but the company’s share price has only increased by 32% per year, which means it is significantly lagging earnings growth.Upcoming Dividend • Dec 21Upcoming dividend of ₩15.00 per shareEligible shareholders must have bought the stock before 28 December 2022. Payment date: 07 April 2023. Payout ratio is a comfortable 2.0% but the company is not cash flow positive. Trailing yield: 0.1%. Lower than top quartile of South Korean dividend payers (3.3%). Lower than average of industry peers (2.4%).Board Change • Nov 16No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 4 experienced directors. No highly experienced directors. No independent directors (4 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.Buying Opportunity • Sep 28Now 20% undervalued after recent price dropOver the last 90 days, the stock is down 32%. The fair value is estimated to be ₩15,184, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 26% over the last 3 years. Earnings per share has grown by 75%. Revenue is forecast to grow by 37% in 2 years. Earnings is forecast to grow by 58% in the next 2 years.Buying Opportunity • Aug 05Now 23% undervalued after recent price dropOver the last 90 days, the stock is down 18%. The fair value is estimated to be ₩20,863, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 17% over the last 3 years. Earnings per share has grown by 37%. Revenue is forecast to grow by 45% in 2 years. Earnings is forecast to grow by 88% in the next 2 years.Buying Opportunity • Jul 12Now 22% undervalued after recent price dropOver the last 90 days, the stock is down 23%. The fair value is estimated to be ₩20,767, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 17% over the last 3 years. Earnings per share has grown by 37%. Revenue is forecast to grow by 45% in 2 years. Earnings is forecast to grow by 88% in the next 2 years.Valuation Update With 7 Day Price Move • Jun 23Investor sentiment deteriorated over the past weekAfter last week's 15% share price decline to ₩17,900, the stock trades at a forward P/E ratio of 15x. Average forward P/E is 10x in the Chemicals industry in South Korea. Total returns to shareholders of 157% over the past three years.Valuation Update With 7 Day Price Move • May 23Investor sentiment improved over the past weekAfter last week's 29% share price gain to ₩26,250, the stock trades at a forward P/E ratio of 22x. Average forward P/E is 12x in the Chemicals industry in South Korea. Total returns to shareholders of 263% over the past three years.Board Change • Apr 27No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 4 experienced directors. No highly experienced directors. No independent directors (4 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.Valuation Update With 7 Day Price Move • Jan 27Investor sentiment deteriorated over the past weekAfter last week's 15% share price decline to ₩19,850, the stock trades at a forward P/E ratio of 42x. Average forward P/E is 10x in the Chemicals industry in South Korea. Total returns to shareholders of 141% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at ₩18,551 per share.분석 기사 • May 09Are Investors Undervaluing Foosung Co., Ltd. (KRX:093370) By 46%?Today we'll do a simple run through of a valuation method used to estimate the attractiveness of Foosung Co., Ltd...분석 기사 • Apr 19Foosung (KRX:093370) Use Of Debt Could Be Considered RiskyThe external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...Reported Earnings • Mar 25Full year 2020 earnings released: EPS ₩65.00 (vs ₩87.00 in FY 2019)The company reported a soft full year result with weaker earnings and profit margins, although revenues improved. Full year 2020 results: Revenue: ₩261.6b (up 5.1% from FY 2019). Net income: ₩5.99b (down 26% from FY 2019). Profit margin: 2.3% (down from 3.3% in FY 2019). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 70 percentage points per year, which is a significant difference in performance.분석 기사 • Mar 08Here's What To Make Of Foosung's (KRX:093370) Returns On CapitalIf you're looking for a multi-bagger, there's a few things to keep an eye out for. Firstly, we'll want to see a proven...공시 • Feb 27Foosung Co., Ltd., Annual General Meeting, Mar 30, 2021Foosung Co., Ltd., Annual General Meeting, Mar 30, 2021, at 10:00 Korea Standard Time.분석 기사 • Feb 14Is Foosung's (KRX:093370) 184% Share Price Increase Well Justified?The worst result, after buying shares in a company (assuming no leverage), would be if you lose all the money you put...분석 기사 • Jan 24Are Investors Undervaluing Foosung Co., Ltd. (KRX:093370) By 25%?How far off is Foosung Co., Ltd. ( KRX:093370 ) from its intrinsic value? Using the most recent financial data, we'll...Is New 90 Day High Low • Jan 19New 90-day high: ₩13,150The company is up 41% from its price of ₩9,300 on 21 October 2020. The South Korean market is up 26% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Chemicals industry, which is up 35% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is ₩17,381 per share.분석 기사 • Jan 02Foosung (KRX:093370) Has A Somewhat Strained Balance SheetDavid Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...Is New 90 Day High Low • Dec 18New 90-day high: ₩11,500The company is up 10.0% from its price of ₩10,500 on 18 September 2020. The South Korean market is up 14% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Chemicals industry, which is up 18% over the same period.분석 기사 • Dec 06Do Institutions Own Foosung Co., Ltd. (KRX:093370) Shares?A look at the shareholders of Foosung Co., Ltd. ( KRX:093370 ) can tell us which group is most powerful. Institutions...매출 및 비용 세부 내역Foosung가 돈을 벌고 사용하는 방법. 최근 발표된 LTM 실적 기준.순이익 및 매출 추이KOSE:A093370 매출, 비용 및 순이익 (KRW Millions)날짜매출순이익일반관리비연구개발비31 Dec 25471,5645,31244,51710,97230 Sep 25462,733-82,04944,57711,36830 Jun 25448,619-96,49145,50810,84131 Mar 25436,341-62,45646,64510,81931 Dec 24437,795-69,35846,05711,15830 Sep 24433,435-32,61546,16610,75930 Jun 24450,433-38,76643,48810,82231 Mar 24478,526-57,16844,42111,70131 Dec 23523,192-53,91741,69811,73130 Sep 23566,21010,79639,66913,91930 Jun 23595,56534,69941,30214,43931 Mar 23605,21458,52038,03617,94631 Dec 22610,56497,04936,27817,74330 Sep 22596,53671,20334,93617,87030 Jun 22550,81774,53532,15417,07931 Mar 22476,62561,28630,53512,33831 Dec 21381,25722,56429,54211,74730 Sep 21314,47031,48428,7129,18830 Jun 21277,86313,96227,1488,76331 Mar 21264,8107,54026,1538,73631 Dec 20261,6009,97726,1378,48230 Sep 20251,433-5,13827,9088,09830 Jun 20244,270-1,34527,0047,85431 Mar 20245,2961,82226,5137,40831 Dec 19248,9448,10026,0917,19530 Sep 19256,63518,65423,3717,43630 Jun 19261,84920,31222,2686,97431 Mar 19269,12528,35521,6406,47731 Dec 18274,93430,83220,8065,86930 Sep 18266,99525,42419,4045,51830 Jun 18263,81929,03119,5575,36531 Mar 18258,83724,22919,6645,40831 Dec 17248,83829,49718,8365,52430 Sep 17238,52872,22718,1775,31330 Jun 17223,86869,25017,5835,07531 Mar 17204,08971,10416,2564,80631 Dec 16192,07365,52416,0414,59030 Sep 16147,02827,49411,9784,15230 Jun 16152,81322,7079,3626,15031 Mar 16160,29218,12814,1994,25531 Dec 15161,15413,75915,1024,19030 Sep 15204,575-51,86919,8094,00730 Jun 15192,891-56,06223,5301,863양질의 수익: A093370는 고품질 수익을 보유하고 있습니다.이익 마진 증가: A093370는 과거에 흑자전환했습니다.잉여현금흐름 대비 순이익 분석과거 순이익 성장 분석수익추이: A093370의 수익은 지난 5년 동안 연평균 50.6% 감소했습니다.성장 가속화: A093370는 지난해 흑자전환하여 5년 평균과 수익 성장률을 비교하기 어렵습니다.수익 대 산업: A093370는 지난해 흑자전환하여 지난 해 수익 성장률을 Chemicals 업계(-3.5%)와 비교하기 어렵습니다.자기자본이익률높은 ROE: A093370의 자본 수익률(1.8%)은 낮음으로 평가됩니다.총자산이익률투하자본수익률우수한 과거 실적 기업을 찾아보세요7D1Y7D1Y7D1YMaterials 산업에서 과거 실적이 우수한 기업.View Financial Health기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/05/27 19:42종가2026/05/27 00:00수익2025/12/31연간 수익2025/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Foosung Co., Ltd.는 7명의 분석가가 다루고 있습니다. 이 중 1명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.분석가기관Rok-ho KimDaishin Securities Co. Ltd.Yumi KimDaiwa Securities Co. Ltd.Byung Hwa HanEugene Investment & Securities Co Ltd.4명의 분석가 더 보기
Reported Earnings • Mar 21Full year 2024 earnings: EPS and revenues miss analyst expectationsFull year 2024 results: ₩668 loss per share (further deteriorated from ₩556 loss in FY 2023). Revenue: ₩437.8b (down 16% from FY 2023). Net loss: ₩69.4b (loss widened 29% from FY 2023). Revenue missed analyst estimates by 6.6%. Earnings per share (EPS) were also behind analyst expectations. Revenue is forecast to grow 21% p.a. on average during the next 2 years, compared to a 11% growth forecast for the Chemicals industry in South Korea. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 57 percentage points per year, which is a significant difference in performance.
Reported Earnings • Mar 24Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behindFull year 2022 results: EPS: ₩1,047 (up from ₩244 in FY 2021). Revenue: ₩610.6b (up 60% from FY 2021). Net income: ₩97.0b (up 330% from FY 2021). Profit margin: 16% (up from 5.9% in FY 2021). The increase in margin was driven by higher revenue. Revenue exceeded analyst estimates by 2.0%. Earnings per share (EPS) missed analyst estimates by 20%. Revenue is forecast to grow 17% p.a. on average during the next 3 years, compared to a 16% growth forecast for the Chemicals industry in South Korea. Over the last 3 years on average, earnings per share has increased by 101% per year but the company’s share price has only increased by 32% per year, which means it is significantly lagging earnings growth.
Reported Earnings • Mar 25Full year 2020 earnings released: EPS ₩65.00 (vs ₩87.00 in FY 2019)The company reported a soft full year result with weaker earnings and profit margins, although revenues improved. Full year 2020 results: Revenue: ₩261.6b (up 5.1% from FY 2019). Net income: ₩5.99b (down 26% from FY 2019). Profit margin: 2.3% (down from 3.3% in FY 2019). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 70 percentage points per year, which is a significant difference in performance.
Major Estimate Revision • May 19Consensus EPS estimates fall by 28%, revenue upgradedThe consensus outlook for fiscal year 2026 has been updated. 2026 revenue forecast increased from ₩564.8m to ₩592.8m. EPS estimate fell from ₩288 to ₩206 per share. Net income forecast to grow 316% next year vs 62% growth forecast for Chemicals industry in South Korea. Consensus price target of ₩20,000 unchanged from last update. Share price fell 4.6% to ₩11,830 over the past week.
New Risk • May 15New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of South Korean stocks, typically moving 17% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Interest payments are not well covered by earnings (2.0x net interest cover). Share price has been highly volatile over the past 3 months (17% average weekly change).
Buy Or Sell Opportunity • May 04Now 28% overvalued after recent price riseOver the last 90 days, the stock has risen 69% to ₩14,130. The fair value is estimated to be ₩11,060, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has declined by 12% over the last 3 years. Meanwhile, the company has become profitable. For the next 3 years, revenue is forecast to grow by 16% per annum. Earnings are also forecast to grow by 52% per annum over the same time period.
Major Estimate Revision • Apr 24Consensus EPS estimates increase by 57%, revenue downgradedThe consensus outlook for fiscal year 2026 has been updated. 2026 revenue forecast fell from ₩579.5m to ₩564.8m. EPS estimate rose from ₩183 to ₩288. Net income forecast to grow 482% next year vs 62% growth forecast for Chemicals industry in South Korea. Consensus price target up from ₩12,000 to ₩20,000. Share price fell 5.4% to ₩13,070 over the past week.
New Risk • Apr 04New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 13% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Interest payments are not well covered by earnings (2.0x net interest cover). Minor Risk Share price has been volatile over the past 3 months (13% average weekly change).
New Risk • Apr 02New major risk - Revenue and earnings growthEarnings have declined by 57% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Interest payments are not well covered by earnings (1.5x net interest cover). Earnings have declined by 57% per year over the past 5 years.
분석 기사 • Jan 28Foosung Co., Ltd. (KRX:093370) Not Lagging Industry On Growth Or PricingWhen you see that almost half of the companies in the Chemicals industry in Korea have price-to-sales ratios (or "P/S...
분석 기사 • Oct 28Revenues Tell The Story For Foosung Co., Ltd. (KRX:093370) As Its Stock Soars 62%Despite an already strong run, Foosung Co., Ltd. ( KRX:093370 ) shares have been powering on, with a gain of 62% in the...
New Risk • Oct 27New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of South Korean stocks, typically moving 11% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Interest payments are not well covered by earnings (0.7x net interest cover). Share price has been highly volatile over the past 3 months (11% average weekly change).
공시 • Oct 24Foosung Co., Ltd. announced that it expects to receive KRW 27 billion in fundingFoosung Co., Ltd. announced private placement of Series 2 Zero Coupon Registered Unsecured Private Convertible Bonds due November 05, 2030 for gross proceeds of KRW 27,000,000,000 on October 23, 2025. The transaction includes participation from Heimdall No.2 PEF for KRW 20,000,000,000 and Fluoro Mateiral New Technology Fund for KRW 7,000,000,000. The bonds bear no interest rate and have a yield to maturity rate of 5.7%. The bonds will mature on November 05, 2030. The bonds are 100% convertible into 3,937,582 shares at a conversion price of KRW 6,857 from the conversion period of November 05, 2026 to October 05, 2030. The bonds have a restriction period of 1 year. The transaction is approved by board of directors of the company and is expected to close on November 05, 2025.
분석 기사 • Oct 17There's Been No Shortage Of Growth Recently For Foosung's (KRX:093370) Returns On CapitalIf we want to find a stock that could multiply over the long term, what are the underlying trends we should look for...
New Risk • Sep 15New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 7.7% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Interest payments are not well covered by earnings (0.7x net interest cover). Minor Risk Share price has been volatile over the past 3 months (7.7% average weekly change).
분석 기사 • Aug 18Foosung Co., Ltd. (KRX:093370) Stocks Shoot Up 30% But Its P/S Still Looks ReasonableKOSE:A093370 1 Year Share Price vs Fair Value Explore Foosung's Fair Values from the Community and select yours Despite...
분석 기사 • Aug 14Is Foosung (KRX:093370) A Risky Investment?Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...
분석 기사 • Jun 10Potential Upside For Foosung Co., Ltd. (KRX:093370) Not Without RiskThere wouldn't be many who think Foosung Co., Ltd.'s ( KRX:093370 ) price-to-sales (or "P/S") ratio of 1.2x is worth a...
Major Estimate Revision • May 02Consensus EPS estimates have been downgraded.The consensus outlook for earnings per share (EPS) in fiscal year 2025 has deteriorated. 2025 revenue forecast decreased from ₩567.0m to ₩550.9m. Now expected to report a loss of ₩49.00 per share instead of ₩69.00 per share profit previously forecast. Chemicals industry in South Korea expected to see average net income growth of 35% next year. Consensus price target down from ₩14,000 to ₩10,000. Share price was steady at ₩4,400 over the past week.
Reported Earnings • Mar 21Full year 2024 earnings: EPS and revenues miss analyst expectationsFull year 2024 results: ₩668 loss per share (further deteriorated from ₩556 loss in FY 2023). Revenue: ₩437.8b (down 16% from FY 2023). Net loss: ₩69.4b (loss widened 29% from FY 2023). Revenue missed analyst estimates by 6.6%. Earnings per share (EPS) were also behind analyst expectations. Revenue is forecast to grow 21% p.a. on average during the next 2 years, compared to a 11% growth forecast for the Chemicals industry in South Korea. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 57 percentage points per year, which is a significant difference in performance.
분석 기사 • Mar 18Would Foosung (KRX:093370) Be Better Off With Less Debt?Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...
공시 • Feb 19Foosung Co., Ltd., Annual General Meeting, Mar 25, 2025Foosung Co., Ltd., Annual General Meeting, Mar 25, 2025, at 10:00 Tokyo Standard Time. Location: auditorium, 72-37, hyundaikia-ro, paltan-myeon, gyeonggi-do, hwaseong South Korea
New Risk • Jan 24New major risk - Revenue and earnings growthEarnings have declined by 15% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 15% per year over the past 5 years. Minor Risk High level of debt (67% net debt to equity).
분석 기사 • Nov 23The Price Is Right For Foosung Co., Ltd. (KRX:093370)When you see that almost half of the companies in the Chemicals industry in Korea have price-to-sales ratios (or "P/S...
분석 기사 • Aug 05Foosung Co., Ltd.'s (KRX:093370) Share Price Is Still Matching Investor Opinion Despite 29% SlumpThe Foosung Co., Ltd. ( KRX:093370 ) share price has fared very poorly over the last month, falling by a substantial...
Major Estimate Revision • May 24Consensus revenue estimates fall by 16%The consensus outlook for revenues in fiscal year 2024 has deteriorated. 2024 revenue forecast decreased from ₩612.4m to ₩516.6m. Forecast loss of -₩107, down from profit of ₩91.00 per share profit previously. Chemicals industry in South Korea expected to see average net income growth of 31% next year. Consensus price target down from ₩20,000 to ₩17,000. Share price fell 3.6% to ₩7,010 over the past week.
New Risk • May 01New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 14% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risk Debt is not well covered by operating cash flow (currently running at an operating cash loss). Minor Risk Shareholders have been diluted in the past year (14% increase in shares outstanding).
공시 • Jan 26Foosung Co., Ltd. has filed a Follow-on Equity Offering in the amount of KRW 101.290324 billion.Foosung Co., Ltd. has filed a Follow-on Equity Offering in the amount of KRW 101.290324 billion. Security Name: Common Stock Security Type: Common Stock Securities Offered: 12,903,226 Price\Range: KRW 7850 Discount Per Security: KRW 39.25 Transaction Features: ESOP Related Offering; Rights Offering
Valuation Update With 7 Day Price Move • Jan 26Investor sentiment deteriorates as stock falls 16%After last week's 16% share price decline to ₩8,620, the stock trades at a forward P/E ratio of 52x. Average forward P/E is 11x in the Chemicals industry in South Korea. Total loss to shareholders of 28% over the past three years.
Upcoming Dividend • Dec 20Upcoming dividend of ₩20.00 per share at 0.2% yieldEligible shareholders must have bought the stock before 27 December 2023. Payment date: 08 April 2024. Payout ratio is a comfortable 17% but the company is not cash flow positive. Trailing yield: 0.2%. Lower than top quartile of South Korean dividend payers (3.5%). Lower than average of industry peers (1.8%).
New Risk • Aug 23New minor risk - Profit margin trendThe company's profit margins are lower than last year and have reduced by more than 30%. Net profit margin: 5.8% Last year net profit margin: 14% This is considered a minor risk. A large drop in profit margin could indicate the company does not have strong competitive advantages or it is yet to establish itself and its core business. Even if it is a well established business, this may make it a much riskier investment than one that has a combination of proven competitive advantages and a stable or growing profit margin. Currently, the following risks have been identified for the company: Major Risks Interest payments are not well covered by earnings (0.1x net interest cover). High level of non-cash earnings (26% accrual ratio). Minor Risk Profit margins are more than 30% lower than last year (5.8% net profit margin).
New Risk • Aug 16New major risk - Revenue and earnings growthEarnings are forecast to decline by an average of 0.1% per year for the foreseeable future. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are expected to decline, then in most cases the share price will decline over time as well. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Interest payments are not well covered by earnings (2.6x net interest cover). Earnings are forecast to decline by an average of 0.1% per year for the foreseeable future. High level of non-cash earnings (22% accrual ratio).
Valuation Update With 7 Day Price Move • Mar 29Investor sentiment improves as stock rises 30%After last week's 30% share price gain to ₩16,620, the stock trades at a trailing P/E ratio of 16.2x. Average forward P/E is 11x in the Chemicals industry in South Korea. Total returns to shareholders of 174% over the past three years.
Reported Earnings • Mar 24Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behindFull year 2022 results: EPS: ₩1,047 (up from ₩244 in FY 2021). Revenue: ₩610.6b (up 60% from FY 2021). Net income: ₩97.0b (up 330% from FY 2021). Profit margin: 16% (up from 5.9% in FY 2021). The increase in margin was driven by higher revenue. Revenue exceeded analyst estimates by 2.0%. Earnings per share (EPS) missed analyst estimates by 20%. Revenue is forecast to grow 17% p.a. on average during the next 3 years, compared to a 16% growth forecast for the Chemicals industry in South Korea. Over the last 3 years on average, earnings per share has increased by 101% per year but the company’s share price has only increased by 32% per year, which means it is significantly lagging earnings growth.
Upcoming Dividend • Dec 21Upcoming dividend of ₩15.00 per shareEligible shareholders must have bought the stock before 28 December 2022. Payment date: 07 April 2023. Payout ratio is a comfortable 2.0% but the company is not cash flow positive. Trailing yield: 0.1%. Lower than top quartile of South Korean dividend payers (3.3%). Lower than average of industry peers (2.4%).
Board Change • Nov 16No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 4 experienced directors. No highly experienced directors. No independent directors (4 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.
Buying Opportunity • Sep 28Now 20% undervalued after recent price dropOver the last 90 days, the stock is down 32%. The fair value is estimated to be ₩15,184, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 26% over the last 3 years. Earnings per share has grown by 75%. Revenue is forecast to grow by 37% in 2 years. Earnings is forecast to grow by 58% in the next 2 years.
Buying Opportunity • Aug 05Now 23% undervalued after recent price dropOver the last 90 days, the stock is down 18%. The fair value is estimated to be ₩20,863, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 17% over the last 3 years. Earnings per share has grown by 37%. Revenue is forecast to grow by 45% in 2 years. Earnings is forecast to grow by 88% in the next 2 years.
Buying Opportunity • Jul 12Now 22% undervalued after recent price dropOver the last 90 days, the stock is down 23%. The fair value is estimated to be ₩20,767, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 17% over the last 3 years. Earnings per share has grown by 37%. Revenue is forecast to grow by 45% in 2 years. Earnings is forecast to grow by 88% in the next 2 years.
Valuation Update With 7 Day Price Move • Jun 23Investor sentiment deteriorated over the past weekAfter last week's 15% share price decline to ₩17,900, the stock trades at a forward P/E ratio of 15x. Average forward P/E is 10x in the Chemicals industry in South Korea. Total returns to shareholders of 157% over the past three years.
Valuation Update With 7 Day Price Move • May 23Investor sentiment improved over the past weekAfter last week's 29% share price gain to ₩26,250, the stock trades at a forward P/E ratio of 22x. Average forward P/E is 12x in the Chemicals industry in South Korea. Total returns to shareholders of 263% over the past three years.
Board Change • Apr 27No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 4 experienced directors. No highly experienced directors. No independent directors (4 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.
Valuation Update With 7 Day Price Move • Jan 27Investor sentiment deteriorated over the past weekAfter last week's 15% share price decline to ₩19,850, the stock trades at a forward P/E ratio of 42x. Average forward P/E is 10x in the Chemicals industry in South Korea. Total returns to shareholders of 141% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at ₩18,551 per share.
분석 기사 • May 09Are Investors Undervaluing Foosung Co., Ltd. (KRX:093370) By 46%?Today we'll do a simple run through of a valuation method used to estimate the attractiveness of Foosung Co., Ltd...
분석 기사 • Apr 19Foosung (KRX:093370) Use Of Debt Could Be Considered RiskyThe external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...
Reported Earnings • Mar 25Full year 2020 earnings released: EPS ₩65.00 (vs ₩87.00 in FY 2019)The company reported a soft full year result with weaker earnings and profit margins, although revenues improved. Full year 2020 results: Revenue: ₩261.6b (up 5.1% from FY 2019). Net income: ₩5.99b (down 26% from FY 2019). Profit margin: 2.3% (down from 3.3% in FY 2019). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 70 percentage points per year, which is a significant difference in performance.
분석 기사 • Mar 08Here's What To Make Of Foosung's (KRX:093370) Returns On CapitalIf you're looking for a multi-bagger, there's a few things to keep an eye out for. Firstly, we'll want to see a proven...
공시 • Feb 27Foosung Co., Ltd., Annual General Meeting, Mar 30, 2021Foosung Co., Ltd., Annual General Meeting, Mar 30, 2021, at 10:00 Korea Standard Time.
분석 기사 • Feb 14Is Foosung's (KRX:093370) 184% Share Price Increase Well Justified?The worst result, after buying shares in a company (assuming no leverage), would be if you lose all the money you put...
분석 기사 • Jan 24Are Investors Undervaluing Foosung Co., Ltd. (KRX:093370) By 25%?How far off is Foosung Co., Ltd. ( KRX:093370 ) from its intrinsic value? Using the most recent financial data, we'll...
Is New 90 Day High Low • Jan 19New 90-day high: ₩13,150The company is up 41% from its price of ₩9,300 on 21 October 2020. The South Korean market is up 26% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Chemicals industry, which is up 35% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is ₩17,381 per share.
분석 기사 • Jan 02Foosung (KRX:093370) Has A Somewhat Strained Balance SheetDavid Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...
Is New 90 Day High Low • Dec 18New 90-day high: ₩11,500The company is up 10.0% from its price of ₩10,500 on 18 September 2020. The South Korean market is up 14% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Chemicals industry, which is up 18% over the same period.
분석 기사 • Dec 06Do Institutions Own Foosung Co., Ltd. (KRX:093370) Shares?A look at the shareholders of Foosung Co., Ltd. ( KRX:093370 ) can tell us which group is most powerful. Institutions...